The following is a summary of “Long-term effectiveness of aripiprazole once monthly on functioning and quality of life in schizophrenia: results of year 2 of the ReLiAM study,” published in the ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

Objective Treatment compliance among psychiatric patients is related to disease outcomes. How to assess patient compliance remains a concern. Here, we established a predictive model for medication ...

A psychiatrist, Dr Yennusom Maalug, has cautioned that, untreated bipolar or mood disorders could lead to serious mental and ...

Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, schizophrenia, and ...

The unique stress that older mothers of vulnerable adult children experience over the holidays is often overlooked. Here's ...

Its pipeline includes treatments for bipolar depression, agitation in Alzheimer’s disease, schizophrenia and Parkinson’s ...

YouGov poll reveals less than half of Scots think public understanding about severe mental illness is better now than it was ...

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported ...

Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – ...

BioXcel Therapeutics (BTAI) announced the achievement of clinical and regulatory progress for its pivotal Phase 3 clinical trials of BXCL501 for the acute treatment of agitation associated with ...

The disorder is a common diagnosis that affects between 2% and 6% of the U.S. population — a higher rate than schizophrenia .